BPA for spinraza
Ended Awarded Last action
- Contract number
- 36E79724A0003
- Awardee
-
Biogen U.s. Corporation UEI E82LHNZSCUA3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $430,578.10
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Biogen U.S. Corporation, a pharmaceutical and biotechnology company specializing in neurological disease therapies, was awarded a single-award Blanket Purchase Agreement (BPA) valued at $430,578.10 by the National Acquisition Center, a civilian federal agency, effective December 4, 2023, through October 29, 2025. This BPA, established under the Pharmaceuticals and Drugs General Services Administration (GSA) Schedule (FSS-61-IB), procures Spinraza, a pharmaceutical product indicated for the treatment of spinal muscular atrophy. The contract was awarded without set-aside restrictions, allowing Biogen to compete on the open market. As a Blanket Purchase Agreement structure, this IDV establishes a framework for the federal government to place delivery orders against the ceiling value for the supply of Spinraza to eligible federal healthcare entities, enabling efficient procurement processes without requiring individual competitive solicitations for each order.
This BPA represents a continuation of Biogen's established relationship with the National Acquisition Center and reflects the federal government's commitment to ensuring consistent access to specialized pharmaceutical treatments for neurological conditions across veteran healthcare systems and other federal agencies. The contract's relatively modest ceiling value, compared to Biogen's other significant IDV for ranibizumab ophthalmic injections valued at $11.4 million, suggests targeted procurement volumes for Spinraza during the performance period. As a firm-fixed-price arrangement, the BPA provides cost certainty for the federal government while leveraging the standardized pricing model established through the GSA Schedule. However, documentation indicates this BPA has been marked for cancellation, suggesting the procurement requirement may have been fulfilled or the need for continued access to Spinraza through this vehicle was subsequently determined to be unnecessary.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Legal Contract Cancellation | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79724A0003?
36E79724A0003 was awarded to Biogen U.s. Corporation by National Acquisition Center (Headquarters) on December 4, 2023.
How much is contract 36E79724A0003 worth?
36E79724A0003's own ceiling is $430,578.
Who can order from contract 36E79724A0003?
36E79724A0003 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79724A0003 under another contract?
Yes. 36E79724A0003 is a blanket purchase agreement under 36F79718D0566, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79724A0003 competed?
The extent of competition for 36E79724A0003 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV